Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

OptiBiotix Health Plc

Healthcare GB OPTI

6.25GBX
0.00(0%)

Last update at 2026-06-05T15:18:00Z

Day Range

6.006.50
LowHigh

52 Week Range

4.6621.00
LowHigh

Fundamentals

  • Previous Close 6.25
  • Market Cap5.42M
  • Volume480521
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.43200M
  • Revenue TTM1.15M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.52M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.86600M -2.04300M 2.44M 6.18M 5.71M
Minority interest - - 0.00000M 0.00000M 0.04M
Net income -1.80500M -2.03900M 2.59M 6.26M 5.80M
Selling general administrative 1.65M 1.70M 0.83M 0.93M 0.74M
Selling and marketing expenses 0.65M 0.12M 0.16M 0.11M 0.17M
Gross profit 0.33M 0.32M 0.24M 1.12M 0.88M
Reconciled depreciation 0.21M 0.20M 0.22M 0.29M 0.25M
Ebit -2.26600M -2.04300M -2.48800M -1.36531M -1.11139M
Ebitda -2.05700M -1.83800M -2.34800M -1.07674M -1.16685M
Depreciation and amortization 0.21M 0.20M 0.14M 0.29M -0.05545M
Non operating income net other - - - - -
Operating income -2.26600M -1.69500M -2.48800M -1.36531M -1.11139M
Other operating expenses 3.14M 2.34M 2.94M 3.58M 2.63M
Interest expense - 0.00000M 5.01M 0.05M 0.04M
Tax provision -0.06100M -0.00400M -0.14600M -0.08452M -0.09163M
Interest income 0.00100M 0.00100M 0.00000M 0.00012M 0.00010M
Net interest income 0.00100M 0.00100M 0.00000M -0.04748M -0.04486M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.06100M -0.00400M -0.14600M -0.08452M -0.09163M
Total revenue 0.87M 0.64M 0.46M 2.21M 1.52M
Total operating expenses 2.60M 2.02M 2.73M 2.49M 1.99M
Cost of revenue 0.54M 0.32M 0.21M 1.09M 0.64M
Total other income expense net 0.40M -0.34800M 4.93M 7.54M 6.82M
Discontinued operations - - - - -
Net income from continuing ops -1.80500M -2.03900M 2.59M 6.26M 5.80M
Net income applicable to common shares - - 2.59M 6.26M 5.80M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.04M 9.40M 11.55M 20.14M 13.70M
Intangible assets 1.12M 1.33M 1.54M 2.64M 2.74M
Earning assets - - - - -
Other current assets 0.02M 0.10M - 1.74M 0.96M
Total liab 0.65M 0.53M 0.64M 1.97M 1.85M
Total stockholder equity 8.40M 8.87M 10.90M 18.14M 11.82M
Deferred long term liab - - - - -
Other current liab 0.10M 0.12M 0.09M 0.18M 0.16M
Common stock 1.96M 1.82M 1.82M 1.76M 1.76M
Capital stock 1.96M 1.82M 1.82M 1.76M 1.76M
Retained earnings 0.58M 1.82M 3.68M 11.32M 5.06M
Other liab - - 0.36M 0.55M 0.56M
Good will - - - - -
Other assets - - - - -
Cash 0.74M 0.64M 1.05M 2.01M 0.86M
Cash and equivalents - - - - -
Total current liabilities 0.37M 0.18M 0.28M 0.60M 0.52M
Current deferred revenue - - - - -
Net debt -0.73900M -0.63500M -1.05200M -1.18809M -0.09292M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - 0.82M 0.77M
Other stockholder equity 4.11M 2.96M 5.40M 5.06M 5.00M
Property plant equipment - - - - -
Total current assets 1.42M 1.38M 1.86M 3.85M 2.01M
Long term investments - - - - -
Net tangible assets - - 9.37M 15.50M 9.08M
Short term investments - - - - -
Net receivables 0.43M 0.46M 0.38M 1.69M 0.93M
Long term debt - - 0.00000M 0.82M 0.77M
Inventory 0.23M 0.19M 0.18M 0.10M 0.18M
Accounts payable 0.27M 0.06M 0.19M 0.42M 0.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.75M 2.27M - - -0.00846M
Additional paid in capital - - - - -
Common stock total equity - - - - 1.76M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 8.15M 13.65M 8.96M
Deferred long term asset charges - - - - -
Non current assets total 7.62M 8.02M 9.69M 16.29M 11.70M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.59M 1.11M -0.33100M -0.19351M -0.35035M
Change to liabilities - - -0.01900M 0.08M -0.04263M
Total cashflows from investing activities 0.59M 1.11M -0.33100M -0.19351M -0.35035M
Net borrowings - - - - -
Total cash from financing activities 1.28M - 0.48M 2.90M 1.69M
Change to operating activities - - - - -
Net income -2.26600M -2.03900M -2.48900M -1.36531M -1.11139M
Change in cash 0.10M -0.41700M -0.95500M 1.14M 0.41M
Begin period cash flow 0.64M 1.05M 2.01M 0.86M 0.46M
End period cash flow 0.74M 0.64M 1.05M 2.01M 0.86M
Total cash from operating activities -1.76800M -1.52700M -1.10900M -1.56466M -0.92796M
Issuance of capital stock 1.28M 0.00000M 0.48M 0.00000M 0.94M
Depreciation 0.21M 0.20M 0.22M 0.29M 0.25M
Other cashflows from investing activities - 1.11M - - -
Dividends paid - - - - -
Change to inventory -0.04100M -0.01000M -0.07600M 0.08M -0.12147M
Change to account receivables 0.03M 0.06M 1.12M -0.90667M -0.03719M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 1.11M -0.33100M 2.90M 0.75M
Change to netincome - - -4.94100M -7.37175M -6.77643M
Capital expenditures 0.00000M 0.00000M 0.17M 0.19M 0.35M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.17M -0.04700M 1.02M -0.74240M -0.20130M
Stock based compensation 0.05M 0.00600M 0.01M 0.06M 0.13M
Other non cash items 0.07M 0.35M 0.12M 0.19M 0.00958M
Free cash flow -1.76800M -1.52700M -1.27700M -1.75817M -1.27831M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OPTI
OptiBiotix Health Plc		 - -% 6.25 - - 4.71 0.64 3.54 -1.3945
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.

OptiBiotix Health Plc

Innovation Centre, York, United Kingdom, YO10 5DG

Key Executives

Name Title Year Born
Mr. Stephen Patrick O'Hara Founder, CEO & Exec. Director NA
Dr. Sofia Kolyda Exec. Director of R&D and Exec. Director 1973
Mr. Rene Kamminga CEO of Functional Fibres & Director NA
Mr. Mark Kingsley Collingbourne CFO & Sec. 1966
Paul Cannings Head of Operations & Quality NA
Kevin James Newman Corp. Devel. Director NA
Mr. Karl Burkitt Marketing Director NA
Mr. Stephen Patrick O'Hara Founder, CEO & Executive Director 1960
Dr. Sofia Kolyda Executive Director of Research & Development and Executive Director 1973
Mr. David Jonathan Blain ACA CFO, Company Secretary & Director 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions